Cobimetinib is approved for treatment of?
High-Yield Explanation
Cobimetinib is approved for RX of melanoma in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in conjunction with Vemurafenib. Cobimetinib - Reversible inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase.